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The Japan National Committee for the Union for International Cancer Control
(UICC) and UICC – Asia Regional Office organized an international session as part
of the 74th Annual Meeting of the Japanese Cancer Association on the topic
“What are the implications of sharing the concept of Universal Health Coverage
for cancer in Asia?” Universal Health Coverage (UHC) is included in the United
Nations’ Sustainable Development Goals and aims to ensure that all people can
receive high-quality medical services, are protected from public health risks, and
are prevented from falling into poverty due to medical costs or loss of income
arising from illness. The session discussed the growing cost of cancer and the
challenges that this poses to the establishment and deployment of UHC in the
Asian region, where countries face budgetary and other systemic constraints in
tackling and controlling cancer. It was noted how sharing concepts on UHC will
assist mutual learning among Asian countries and help in the formation of guideli-
nes that can be adapted to national and regional realities. Presentations included
a status report on UHC for cancer control in Thailand, and a report from the WHO
Kobe Centre concerning prospects for collaborative research on UHC. Also dis-
cussed were the current status of cancer burden and control in China and Korea
and Japan’s progress in systemizing cost-effectiveness evaluation. The final pre-
sentation highlighted the importance of gathering social and economic data across
Asia in order to build a picture of commonalities and differences in the region.
T he Union for International Cancer Control (UICC) is amembership organization that exists to help the global
health community accelerate the fight against cancer. Founded
in 1933 and based in Geneva, UICC’s growing membership of
over 760 organizations across 155 countries features the
world’s major cancer societies, ministries of health, research
institutes, and patient groups. Together with its members, key
partners, the WHO, World Economic Forum, and others, UICC
is tackling the growing cancer crisis on a global scale. As part
of the official program of the 74th Annual Meeting of the
Japanese Cancer Association the Japan National Committee
for UICC and UICC – Asia Regional Office (ARO) organized
an international session to discuss the topic “What are the
implications of sharing the concept of Universal Health Cover-
age (UHC) for cancer in Asia?” The UICC International Ses-
sion was held shortly after the historic adoption of the 2030
Agenda for Sustainable Development by the United Nations
(UN), in which UHC is included among the Sustainable
Development Goals. The objectives of UHC are to ensure that
all people can receive high-quality medical services, are pro-
tected from public health risks, and are prevented from falling
into poverty due to medical costs or loss of income arising
from illness. These objectives accord with the principles of the
UICC World Cancer Declaration. An urgent challenge facing
cancer specialists is to share a common awareness of UHC,
given that cancer faces unique difficulties for the establishment
and deployment of UHC. Cancer in Asia is characterized by
its diversity and difficulty in sharing measures due to differ-
ences in medical care standards. The session sought to share
concepts on UHC that will serve to assist mutual learning
among Asian countries according to their level of develop-
ment. Experts in various fields and from the countries of
China, Korea, Japan, and Thailand gave presentations. The ses-
sion was co-chaired by Hideyuki Akaza, Strategic Investiga-
tion on Comprehensive Cancer Network, Interfaculty Initiative
in Information Studies ⁄Graduate School of Interdisciplinary
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Information Studies, University of Tokyo (Tokyo, Japan), Xis-
han Hao, Chinese Anti-Cancer Association (Tianjin, China),
and Jae Kyung Roh, Yonsei Cancer Center, Yonsei University
College of Medicine (Seoul, Korea).
Introduction: The Purpose of the UICC International
Session
Hideyuki Akaza noted that rapid economic growth and pro-
longed life expectancy in Asia have resulted in the emergence
of an aging society. This aging society has resulted in an
increase in cancer incidence and expanding medical costs.
Furthermore, there are different levels of health-care stan-
dards and investment in social security in Asia has created
unbalanced medical equity. Diverse physician and patient
views with regard to cancer treatment also arise through differ-
ent socio-economic backgrounds and cultural differences.
On September 25, 2015, the United Nations adopted the
2030 Agenda for Sustainable Development. These 17 sustain-
able development goals (SDGs) and 169 targets will drive
efforts to end extreme poverty and fight inequality. They also
represent a historic moment for the non-communicable disease
(NCD) community.
The third of the SDGs states:
Ensuring healthy lives and promoting the well-being for all at all ages is
essential to sustainable development. Significant strides have been made in
increasing life expectancy and reducing some of the common killers asso-
ciated with child and maternal mortality. Major progress has been made
on increasing access to clean water and sanitation, reducing malaria, tuber-
culosis, polio and the spread of HIV ⁄ AIDS. However, many more efforts
are needed to fully eradicate a wide range of diseases and address many
different persistent and emerging health issues.(1)
In addition, one of the targets included in the Agenda is:
Achieve universal health coverage, including financial risk protection,
access to quality essential health-care services and access to safe, effective,
quality and affordable essential medicines and vaccines for all.
This represents a concrete commitment to UHC by the UN.
Various countries are adopting reforms toward UHC.
When we consider cancer we have to address both economic
issues and the emergence of aging societies. The ratio of mortal-
ity to incidence is very high in low income countries, rising to as
high as 80% for some cancers. The issue of the aging society is
also presenting challenges for UHC. Already in Japan, in 2015,
the proportion of the population over 65 years of age is over
25%. Consideration will need to be given to how to respond to
increased cancer incidence due to the aging of society.
In the specific case of prostate cancer in Japan, the great
majority of cases (70–80%) emerge in patients 65 years and
older. It can naturally be expected, therefore, that an aging
society will experience an upturn in cancer incidence. This
increase in incidence also entails increases in treatment costs.
New agents for prostate cancer are emerging, but all of these
are expensive.
Indeed, recent medical developments have seen increases in
the provision of more expensive types of treatment to treat
conditions that were previously untreatable. In addition, these
new drugs are being used to treat people who would previ-
ously have been untreated. The reasons for this are the increas-
ing safety of intervention, more acceptable and less invasive
interventions, changing attitudes to chronological age as a rea-
son for refusing treatment, and changing expectations about
health and disease.
Asian countries present a diversity of economic levels and
health-care resources. In an article submitted to The Lancet
Oncology in 2013,(2) a study reported on the treatment of
clinically localized prostate cancer according to the level of
health-care resources, divided by “basic level,” “limited level,”
“enhanced level,” and “maximum level.” The therapeutic costs
for prostate cancer vary considerably according to these levels
and “maximum level” treatment may be difficult for countries
to provide.
The economic burden of cancer in Asian countries was dis-
cussed at the UICC-ARO Session at the UICC World Cancer
Congress in Melbourne, Australia, in December 2014 and also
at a UICC-ARO and UICC Japan roundtable meeting. The
details of the roundtable discussion in Melbourne were subse-
quently published in the Asian Pacific Journal of Cancer
Prevention.(3)
The discussions at this UICC International Session will con-
tinue the discussions that took place in Melbourne in 2014,
with various speakers addressing the issue from various
perspectives.
How Does a Middle Income Country Like Thailand Provide
Universal Access to Cancer Prevention, Treatment, and
Care Under the UHC Policy?
Suwit Wibulpolprasert (International Health Policy Program,
Ministry of Public Health, Thailand) noted that it is very
timely to discuss UHC given increasing pressures on health-
care systems due to increasing incidence and aging. He noted
that Thailand may provide a good example of how a middle
income country has worked to provide universal access to can-
cer prevention, treatment, and care.
Thailand has had UHC since 2002. At that time per capita
gross domestic product (GDP) was a mere $US1900. The
Government is committed to UHC, and currently 17% of the
total national budget is spent on health. Out-of-pocket payment
is 12% of total health expenditure. The total health expenditure
represents <6% of GDP. There is universal population cover-
age, and health care is provided free at point-of-service, with
negligible co-payment requirements. Services are comprehen-
sive, including prevention and promotion and essential drugs,
including anticancer drugs. In terms of coverage for cancer,
the main items for coverage are cancer prevention, screening,
treatment, and palliative care.
Thailand has limited resources and therefore it focuses
strongly on cancer prevention activities. For example, there is
strict control of tobacco and alcohol, through the Tobacco
Control Act (1992) and Alcohol Control Act (2007). There is
also a “sin tax” that stipulates an addition 2% levy on excise
tax on tobacco and alcohol products, which is provided to the
Health Promotion Fund managed by the Thai Health Promo-
tion Foundation, the chair of which is the Prime Minister. The
fund receives approximately $US115 million each year. Vacci-
nes are being provided for hepatitis B and human papilloma
virus vaccination programs are also currently being piloted in
Thailand, with a view to expanding coverage nationwide.
With regard to cancer screening, currently only Pap-smears
and visual inspection with acetic acid are covered for persons
aged 30–60 years every 5 years. These efforts have accom-
plished 68% coverage in 2013. Measures are being taken to
explore colorectal and gastric cancer screening for high risk
populations, as well as once-in-a-lifetime hepatitis B screening
and the use of the American Stop Smoking Intervention Study
for Cancer Prevention for tobacco and alcohol screening under
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UHC. Mammography screening is not considered cost-effec-
tive under UHC and delivery capacity is not affordable.
When UHC was launched in Thailand in 2002, cancer treat-
ment was not initially covered. However, from 2005 cancer
treatment was included under UHC due to high demand and the
cancer treatment network has since expanded. There are cur-
rently 22 networks and 641 centers around the country. The
provider is paid through diagnosis-related groups in a bundled
payment. Standard protocols for priority cancers have been
developed since 2008, in cooperation with the Cancer Associa-
tion of Thailand, and there are now 12 protocols in place. Pay-
ment for treatment is fixed, based on diagnosis-related groups
(inpatients) and fee schedules for the protocol (outpatients).
The fee schedule system was developed learning from the sys-
tem in operation in Japan. High-price drugs are being paid for
separately. The total cost of cancer treatment in the UHC sys-
tem of Thailand was 6% of the total UHC budget in 2014,
which is less than the burden of disease for cancer in Thailand.
The UHC system in Thailand does not include all cancer
drugs that are registered in Thailand in its benefit package,
unlike in Japan, where all registered drugs are covered. Of the
more than 2000 drugs registered in Thailand, there are a total
of 735 drugs on the national essential drugs list, which is sub-
divided into lists, ranging from A to E. List D items (139
items) are medicines that require expert diagnosis and include
high-price anticancer drugs. List E items (42 items, divided
into E(1) and E(2)) include very highly priced specialized
medicines that require pre-approval, including anticancer
drugs, such as trastuzumab and letrozole, which have recently
been added to the list. Seven of these List E medicines are
under compulsory licensing due to a failure in negotiations
with pharmaceutical companies.
For the reimbursement of highly priced anticancer drugs, a
central bargaining system is in place, with central government
procurement being implemented for List E(2) items (including
seven anticancer drugs), with the medicines being distributed
through vendor-managed inventory to the medical facilities.
List D items (16 anticancer drugs) are procured through local
purchasing, with the medical institutions being reimbursed in
cash, within the price negotiated through central bargaining.
The Health Intervention and Technology Assessment (HITA)
program is often used to support price negotiations with phar-
maceutical companies as means of seeking cost-effective pro-
vision in the Thai health-care setting. For example, in the case
of oxaliplatin, the original price was set at THB8000. How-
ever, the use of HITA showed that the threshold price that
would make oxaliplatin cost-effective in the Thai setting was
THB5000 THB. The government then negotiated a reduced
price of THB2500 THB with the drug company, in line with
government budget limitations. The government engages in
these central negotiations in order to ensure that high price
drugs are available for patients in Thailand.
When the abovementioned centrally based price negotiations
fail, it is possible for government-use licenses (GUL; compul-
sory licensing) to be implemented (under the stipulations of
TRIPS Article 31b, and the Patent Act of Thailand, Article
51). The government has implemented GUL for seven essential
medicines, including four antineoplastic drugs. The implemen-
tation of GUL has had the effect of achieving considerable
price savings and provides a stimulus to pharmaceutical com-
panies to engage in price negotiations.
In terms of palliative care, the National Palliative Care Strat-
egy was approved by the National Health Assembly and
Commission in 2014. This strategy focuses on family- and
community-based care, supported by health facilities. Financial
support is provided under UHC for pain treatment, oxygen,
and chronic ulcers. The palliative care network now extends to
65 nodes with 549 centers and 363 friendship (self-help) nodes
with 1618 centers.
Remaining challenges for Thailand include the formation of a
cancer registry. Risk factors still exist, although tobacco use has
decreased to 18–19% of the population. One of the biggest chal-
lenges is to expand services, incorporating protocols, surgery,
pathology, radiology, oncology, and palliative care. Further
efforts also need to be made to respond to the issue of very high-
priced drugs. Another challenge is to fully harmonize the three
major health insurance funds in Thailand under UHC.
Discussion. A participant from Kumamoto, Japan, referred to
the constantly increasing cost of drugs and asked if Thailand
engages in efforts to evaluate the cost effectiveness of new
drugs, in a similar way to the National Institute for Health and
Care Excellence (NICE) in the UK. He noted that there is no
mechanism in Japan to evaluate cost effectiveness.
Suwit Wibulpolprasert responded that HITA program is
positioned within the Ministry of Health of Thailand and has
cross-linkage to NICE. The HITA program is used as a means
of working closely with colleagues across the region to evalu-
ate cost effectiveness. In Thailand, items for evaluation also
include budget impact, drug delivery, and equity of access, in
addition to cost effectiveness. There are now 22 radiotherapy
centers all over Thailand and the private sector is being
increasingly involved, at a price that is the same as those ser-
vices provided by the public facilities.
Jae Kyung Roh (Yonsei University College of Medicine,
Korea) added that in Korea there is a very similar system,
where the Health Insurance Reimbursement Agency (HIRA)
determines cost effectiveness, in a similar manner to NICE.
Suwit Wibulpolprasert noted that HITA works closely with
National Evidence-based healthcare Collaborating Agency and
HIRA of Korea and it is likely that collaboration will continue
to increase in the future.
Advancing NCDs in UHC and Possible Role of WHO Kobe
Centre
Shinjiro Nozaki (WHO Kobe Centre, Japan) noted that in
September 2015 the UN adopted new SDGs in the 2030
Agenda for Sustainable Development. The government of
Japan has placed priority on global health governance and
healthy aging and recently a WHO Global Forum on Innova-
tions for Ageing Populations(4) was held at the WHO Kobe
Centre. When considering UHC and healthy aging, NCDs are
a major target, and in 2011 the UN General Assembly adopted
the Political Declaration for Prevention and Control of NCDs.
The WHO is engaged in a variety of operations and initiatives
to tackle NCDs.
On October 1, the WHO published the first World Report on
Health and Aging.(5) In this report, NCDs are a major target
for research and program implementation. The WHO definition
of UHC is as follows:
Universal health coverage (UHC) is defined as ensuring that all people can
use the promotive, preventive, curative, rehabilitative and palliative health
services they need, of sufficient quality to be effective, while also ensuring
that the use of these services does not expose the user to financial
hardship.
This definition of UHC embodies three related objectives: (i)
equity in access to health services – those who need the
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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services should get them, not only those who can pay for
them; (ii) that the quality of health services is good enough to
improve the health of those receiving services; and (iii) finan-
cial-risk protection – ensuring that the cost of using care does
not put people at risk of financial hardship.
All member states of the WHO have endorsed the definition
of UHC and the WHO is developing a plan of action for the
future. Universal health coverage provides a good opportunity
to rethink and re-orient health systems and the WHO is consid-
ering the following approaches: (i) emphasis on prevention and
health promotion and quality of services; (ii) community
engagement and person-centred approaches; (iii) defining ser-
vices, including rehabilitation and palliative care; (iv) integra-
tion within health systems and across sectors, including
considerations of well-being in addition to health; (v) priority
for most vulnerable groups; and (vi) health financing and
social safety nets, with effective policy coherence. The major
agenda items for UHC are: (i) health service delivery; (ii) fol-
low-up for Millennium Development Goals; (iii) health-care
financing; (iv) human resources for health; and (v) affordable
and accessible medicines and health technologies.
The government of Japan has launched a new strategy on
global health diplomacy in 2013 and this policy will be a
focus for the G7 Health Ministers’ meeting in 2016 in Japan.
In discussions with the government of Japan, the WHO has
suggested that it would be beneficial for Japan to share useful
lessons from its experiences with other countries, including
comprehensive health services for citizens, universal health
insurance system, long-term care insurance, medical expendi-
ture control system, and innovation for NCDs. Japanese soci-
ety entered the era of the super-aged society in 2007 and in
2012 it is estimated that 24.1% of the population is aged
65 years and over. The aging society will create new health
needs and opportunities for early prevention and health promo-
tion (particularly for NCDs), and Japan is well positioned to
share its experiences.
In other Asian countries also, the aging society has already
started or is projected to start in the near future. Aging soci-
eties create new social and health needs. These include the
need for financing strategies and incentives, NCD prevention
and control initiatives, and community models of care and sup-
port. Given the new needs arising in aging societies, the gov-
ernment of Japan has proposed a new Nippon Initiative on
UHC.
The WHO Kobe Centre is expected to become a think-tank
within the WHO, which will have convening power. The
Kobe Centre is looking to act as an interface across the issues
of UHC, innovation, and aging, with cross-cutting research
activities and other emerging issues (e.g. dementia). Linkage
with the Japanese government’s Nippon Initiative on UHC is
also planned and the center is seeking to collaborate with
Japanese and international academic institutions. In addition,
an annual global forum on UHC, innovation, and aging is also
planned.
Discussion. Jae Kyung Roh noted that usually the WHO and
the World Bank tend not to be oriented to Asia. He requested
that the WHO Kobe Centre work to identify methods of
engaging in research that is more relevant to Asia.
Shinjiro Nozaki responded that the WHO Kobe Centre is a
global research center and is not able to focus exclusively on
issues facing a certain region. However, there are moves to
identify subthemes for research and establish research priori-
ties. There are plans to hold a consultation on a future research
agenda for the center and this consultation exercise will
include experts and academics from various countries, includ-
ing emerging economies in Asia.
Cancer Burden and Control in China
Xishan Hao (Chinese Anti-Cancer Association, China) noted
that the global cancer burden has continued to grow and can-
cer is now a significant cause of mortality in many countries.
There are differences between incidence and mortality between
countries. In developed countries the mortality rate is less than
the incidence rate, but this situation is reversed in developing
and emerging countries.
In urban China, between 1990 and 2011, the proportion of
all deaths caused by cancer rose from 21.9% to 27.8%. In the
case of rural China, the proportion increased from 17.5% to
23.6% over the same period. From 1989 to 2008 the cancer
incidence for all cancers has increased from 184.81 per
100 000 population to 286.69. This figure suggests that one in
four people in China will experience cancer during their life-
time.
As already noted by Hideyuki Akaza above, cancer is an
age-related disease and cancer incidence increases along with
increases in the population’s mean age. The top cancer inci-
dence and mortality rates in China for men are lung, stomach,
liver, colorectal, and esophagus; for women, they are breast,
lung, colorectal, stomach, and liver (China Health Statistics
Yearbook 2011).
In terms of challenges for cancer control in China, the major
challenge is to reduce lifestyle-related risk factors. Nearly one-
third of the world’s smokers live in China and the male smok-
ing rate still stood at 52.9% in 2010. The government of China
has recently decided to engage in further measures to
strengthen tobacco control. In terms of perceptions of cancer,
a study has shown that people in China tend to perceive cancer
pessimistically or fatalistically, with 43% of Chinese people
responding that “cancer = death.”(6)
In terms of other efforts at cancer control, the government’s
program of vaccination for hepatitis B has resulted in a reduc-
tion in the prevalence rate of hepatitis B surface antigen carri-
ers in children aged <5 years from 9.6% in 1992 to 0.96% in
2006.
The Chinese National Breast Cancer Screening Program
(2008–2009) provided free screening services to asymptomatic
women in regions of 30 provinces, as part of the Early Detec-
tion and Early Treatment of Cancer program. The goals of the
Chinese National Breast Cancer Screening Program included:
(i) to perform breast cancer screening among the high-risk-age
population and to promote women’s health at the community
level; (ii) to improve the doctor’s screening skills in local
areas and to establish cancer primary prevention and health-
care systems; and (iii) to develop screening strategies for
breast cancer prevention in China. The program was govern-
ment-funded and targeted women aged between 35 and
69 years. A total of 910 830 women were screened and 466
cancer cases were detected.(7) This study confirmed that early
detection and proper treatment is essential for breast cancer.
The second phase of breast cancer screening was imple-
mented through the Multi-modality Independent Screening
Trial (2008–2010. Eligible women were examined by clinical
breast examination, mammography, and breast ultrasound, con-
currently. The proportion of early-stage in screening-detected
breast cancer was larger than that found in clinical-detected
breast cancer. Smaller cancers with less lymphatic metastasis
were also found in screened cancer.(8)
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In China, further efforts are planned in expanding UHC and
China will continue to work in collaboration with other
countries.
Discussion. Jaeyong Shin (Yonsei University College of Medi-
cine, Korea) asked whether there are plans in China to expand
the cancer screening plan to gastric cancer or colorectal cancer.
With regard to anticancer drugs, he asked whether there are
regional disparities concerning the drugs that are available.
Xishan Hao responded that China has 31 provinces, each of
which has their own policies concerning health-care, although
UHC programs are not very advanced. The central government
provides funds to provincial governments to organize their
own programs. In terms of screening for gastric and colorectal
cancer, while it would undoubtedly be valuable to engage in
research and screening, there are few national government
grants available. On the local level, various gastric and col-
orectal cancer screening studies are underway.
Korean Experiences of UHC and Cancer Control – Focusing
on the National Cancer Screening Program
Eun-Cheol Park (Yonsei University College of Medicine,
Korea) noted that the National Cancer Screening Program
(NCSP) was launched in 1999. The background to the launch
of the NCSP was the increasing burden of cancer in both epi-
demiologic and economic aspects. In 1999 the cancers with
the highest incidence were stomach, lung, liver, colorectal,
breast, and cervical.
In 1999, screening was launched for stomach, breast, and
cervical cancer, but covered initially just 3% of the population,
although Medical Aid covered all costs. In 2002, the program
was extended to a larger proportion of the population and the
costs were covered by Medical Aid and health insurance
premiums. The program was expanded to include liver cancer
screening in 2003 and colorectal cancer in 2004. Within a per-
iod of 6 years, from 1999 to 2005, UHC was achieved for can-
cer screening for five cancers in Korea.
Over the course of 10 years, since 2004, the participation
rate in screening for cancer has increased overall from 38.8%
to 67.3% and most screening is implemented as organized,
rather than opportunistic, screening.
National screening guidelines were developed in 2002 by the
Ministry of Health and Welfare, with the cooperation of the
National Cancer Center and academic societies, which set out
the content of services for screening and the target age range.
In terms of cost-effectiveness of screening, one characteristic
of screening in Asia is the low cost-effectiveness of breast can-
cer screening in comparison to Western countries. This is attri-
butable to the lower rate of incidence of breast cancer in Asia.
From 2005 an initiative was launched to develop guidelines
for screening quality in breast and other cancers. A pilot pro-
ject was implemented in five hospitals from 2006 to 2007 and
a major project was implemented for 3 years from 2008 in
general hospitals and clinics, with a total of 2000 screening
units. Cancer screening units were subject to a 13-point evalu-
ation, with each unit being provided with feedback. The result
of this initiative was a significant increase in the sensitivity of
the NCSP for breast and liver cancers.
The contributing factors to Korea’s successful achievement
of UHC in cancer screening are the fact that universal cover-
age under national health insurance and Medical Aid already
covered the population. The 10-Year Plan for Cancer Control
and government initiatives also helped to drive UHC in cancer
screening to a successful conclusion. Universal health coverage
in cancer screening has helped to improve the 5-year relative
survival rate for all cancers and screening participation rates
have also increased.
In terms of further challenges, there is a need for evidence-
based guidelines in Korea and efforts will be required to fur-
ther boost the quality of screening. Thyroid cancer has been
increasing in incidence in recent years and measures for
screening for this type of cancer are needed. It will also be of
particular importance to share experience among Asian coun-
tries to further improve guidelines and make them relevant to
the Asian context.
Discussion. Hideyuki Akaza asked what measures are being
implemented for screening of prostate cancer in Korea.
Eun-Cheol Park responded that new guidelines have recently
been issued, which have added lung, thyroid, and prostate can-
cer screening. The final recommendations of the new guideli-
nes stipulate that screening for thyroid and prostate cancer
should be provided to high-risk populations.
Jae Kyung Roh added that the blood test for prostate cancer is
very simple and it would be advisable to include screening for
prostate cancer in the national program. In addition, for colorec-
tal cancer it would be more effective, although more expensive,
to include endoscopy as part of the screening program.
Cost Effectiveness of Cancer Care in Japan
Takashi Fukuda (National Institute of Public Health, Japan)
noted that, according to the WHO World Health Report
2010,(9) there are three dimensions to consider when moving
towards universal coverage. These are direct costs (proportions
of the costs covered), services (which services are covered?),
and population (who is covered?). Ideally, the concept of UHC
is achieved when all individuals are covered and can receive
all kinds of care with no limitation on health-care budget.
In Japan the public health insurance scheme covers the whole
population. However, there are approximately 3000 health insur-
ance bodies. Some of them are occupation-based, for example, a
large company organizes its own health insurance body, and
some are community based. People in Japan have to join one of
the health insurance bodies. In 2010, Annual Medical Expendi-
ture is ¥37 trillion, which is approximately 8.3% of GDP.
Medical expenditure has continued to increase by approxi-
mately ¥1 trillion every year. One of the reasons for increasing
medical expenditure is population aging. The proportion of
elderly people occupies 23% of the whole population. How-
ever, another big reason is increasing technologies in health
care, such as advanced medical equipment and new drugs.
In terms of the funding sources for medical expenditure, less
than half (49%) of the expenditure is borne by health insurance
premiums. Thirty-eight percent of the expenditure is paid by tax
from the central and local governments. The proportion of tax
payment is increasing every year. Patients’ out-of-pocket pay-
ments account for approximately 13% of total expenditure.
Expenditure is increasing in Japan not only due to popula-
tion aging, but also due to innovation of new technologies,
with new advanced diagnostic and treatment technologies hav-
ing been introduced. If insurance premiums or tax funding are
limited, it will be necessary to consider efficient use of the
health-care budget.
If a new technology is more effective compared to the old
one, it should be covered by health insurance schemes that
cover the whole population. In this case, people must agree to
bear increasing expenditure. Conversely, it may be possible to
prioritize cost effective technologies.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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Health insurance coverage decisions and reimbursement
prices are determined by the Ministry of Health, Labor and Wel-
fare and are not dependent on health insurance bodies. Prices are
revised every 2 years and the Ministry has to consult with the
Central Social Insurance Medical Council (CSIMC).
In terms of debate with CSIMC, the Cost Effectiveness
Evaluation Committee was established in April 2012, including
health-care insurers and providers, as well as members of gov-
ernment, industry, and medical experts. The issues discussed
by the committee are: (i) a basic concept for a system for
cost-effectiveness evaluation; (ii) operational process of cost-
effectiveness evaluation; and (iii) application of results. To
date, a total of 28 meetings have been held.
In June 2015 the government of Japan issued its Basic Pol-
icy on Economic and Fiscal Management and Reform 2015, in
which it was noted that:
. . . it will consider the cost-effectiveness of insurance coverage of medi-
cine and medical devices as a way to cope with the sophistication of
healthcare. The government will introduce such cost-effectiveness analysis
on a trial basis for the FY2016 revision of remunerations for medical treat-
ment. Subsequently, it will seek to promptly introduce cost-effectiveness
analysis on a full-fledged scale.
The possible process for evaluation will include: topic selec-
tion, primary analysis submitted by manufacturers, review and
re-analysis by expert groups, appraisal, and a decision. Eco-
nomic evaluation will not be the only rule for decision-mak-
ing, with other aspects, such as ethical and social factors, also
being taken into account.
The Cost Effectiveness Evaluation Committee has discussed
how to prioritize technologies to be evaluated. It is likely that
evaluation will begin with existing medicines and medical
devices, in order to avoid delays to insurance coverage.
The methods of analyses include taking into account a
health-care payer perspective. In addition, quality-adjusted life
years will be a primary outcome measure. Evaluation guideli-
nes will be proposed by the academic members of the commit-
tee, with local data being requested from research groups and
academic societies in order to support analyses.
In terms of appraisal and decision-making, it is anticipated
that a new appraisal committee will be established under the
CSIMC. Not only the results of cost-effectiveness analyses,
but also ethical and social aspects of the treatment will be con-
sidered by the committee. The results of analyses and apprai-
sals will be mainly used for pricing adjustment, not for
insurance coverage decisions. Preparations are underway to
implement cost-effectiveness analysis on a trial basis from
April 2016.
Discussion. Shigeo Horie (Juntendo University, Tokyo, Japan)
noted that cost-effectiveness analyses mainly focus on critical
outcomes, quality-adjusted life years, and medical expenditures.
However, he asked how the introduction of a medical device that
may improve hospital efficiency overall would be evaluated.
Takashi Fukuda responded that individual technology assess-
ments focus on the results and cost of the treatment. Evalua-
tion of overall hospital efficiency is a separate matter, although
it may be discussed within the process.
Universal Health Coverage and Interdisciplinary Research:
The Significance of Cross-Boundary Cancer Studies
Jae Kyung Roh (Yonsei University College of Medicine,
Korea) noted that Asia has huge populations with diverse
ethnicity and cancer prevalence is increasing among Asian
countries. However, appropriate guidelines for cancer control
suited to Asian people are still urgently needed. It is important
for Asian countries to prepare guidelines that can respond to
diverse socio-economic conditions.
In Korea, cancer become the most common cause of
death in 1983. Cancer incidence is increasing rapidly, but
the survival rate has also improved significantly during the
last three decades. The socio-economic environment of
Korea is characterized by a mandatory national health insur-
ance system, coupled with a NCSP and voluntary check-ups
for early detection. There is also aggressive competition
between the big five hospitals in Seoul. The national life-
style of Korea has also changed in recent years, with
increased urbanization, improved hygiene, and an ongoing
Westernization of diet.
The number of cancer patients is increasing by approxi-
mately 6% annually, with incidence of breast, colon, thyroid,
lung, bladder, and prostate cancers increasing, compared with
declines in uterine, cervical, stomach, and liver cancer. Five-
year survival rates are up from 41.2% in 1993–1995, to 68.1%
in 2008–2012. The improvements that have been achieved
over the last three decades are probably due to a number of
factors: (i) primary prevention, including education, improved
hygiene, and antismoking campaigns; (ii) vaccination for hep-
atitis B and human papilloma virus; (iii) NCSP for early detec-
tion; and (iv) mandatory national health insurance leading to
improvement of treatment methods and multimodality team
approaches.
The Japan–Korea Bilateral Joint Seminar on Cross-Boundary
Cancer Studies Toward the Cancer Cure in Asia was held at
Yonsei University, Seoul in February 2014. It was organized
by Yonsei University and the University of Tokyo, and was
sponsored by the National Research Foundation of Korea and
the Japanese Society for the Promotion of Science.
The seminar was held against the backdrop of the increasing
incidence of cancer in the Asia-Pacific region and the impor-
tance of interdisciplinary research efforts between Asian coun-
tries. It provided a common working platform to bring
together both medical and non-medical fields. It represented a
significant first step towards international and interdisciplinary
efforts to be extended to China and the wider Asian region.
Interdisciplinary discussions on cancer from medical, pharma-
ceutical, anthropological, and social points of view sought to
create a new knowledge network on existing networks in
diverse fields. It is hoped that a second seminar can be held in
the near future.(10–12)
How do People in Asia Perceive Cancer-Related Issues?
Shigeto Sonoda (University of Tokyo, Japan) noted that his
presentation would be discussing public health in general,
rather than cancer specifically. He explained that he is from a
sociology background and has sought to attempt macroeco-
nomic data to examine commonalities and differences across
Asia.
Many people talk about Asia, but the scope and concept of
Asia are different from person to person. The concept of the
Asianization of Asia is that Asia is coming to be viewed and
to be understood as a whole. In order to understand Asia from
a scientific point of view, it is important to gather data. Unless
all countries share a common understanding about the neces-
sity of data collection it would not be possible to gain a full
picture about Asia. There is a dynamic relationship between
the understanding of Asia and the collection of data. There are
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some data archives that have been accumulated to date, includ-
ing the AsiaBarometer and the East Asia Social Survey.
The information that these data have provided have been
interesting and highlighted differences in perceptions within
the Asian region. With regard to a question concerning “Rela-
tive trust with public health system” that was included in the
AsiaBarometer survey, people in different countries gave dif-
ferent responses, with Chinese people indicating a lower level
of trust than people in Japan and Korea. Responses to a ques-
tion about “Relative expectations of government expenditure
for public health” also showed significant differences from
country to country, with Japan reporting high expectations and
China reporting considerably lower expectations.
Commonalities among countries can be found in a cohort
analysis of East Asian countries, where it has been found that
people’s opinions on the perceived importance of health tend
to increase with age, while satisfaction with health decreases
with age (with Hong Kong being an exception in this case).
The East Asia Social Survey, which was implemented in
2010, focused on public health issues. Even though public
health systems have been created, they cannot work properly
unless they are effectively utilized; the survey was imple-
mented with the aim of identifying means of making system
utilization more effective. In response to the question “How
much do you worry about being unable to receive healthcare
when needed?” the responses of people in Japan and Korea
were similar, whereas a greater proportion of people in China
cited great concerns about receiving healthcare. In terms of
hindrances to healthcare, differences between Japan, Korea,
and China are also very distinct. By looking into the mindsets
of people in the different countries of Asia, it may be possible
to elucidate ways of enhancing the effectiveness of health-care
systems and delivery.
There are various variables that could be included in poten-
tial questions in an “Asia Cancer Barometer,” including health
conditions, health check-ups, and exercise, care management,
medical insurance, and socio-economic conditions. The cre-
ation of an “Asia Cancer Barometer” will enable study of the
social dimensions of cancer in Asia and will empower fruitful
cross-national interdisciplinary research on UHC for cancer. It
is important to create a common archive of information and
exchange ideas in Asia as a means of identifying new direc-
tions for cross-boundary research.
General Discussion
Norie Kawahara (University of Tokyo, Japan) noted that, since
2009, the Asia Cancer Forum has been engaged in the global
health agenda. It is truly exciting that the SDGs have been
recently adopted by the UN. However, in the cancer commu-
nity there is still a lack of understanding and consideration
about the importance of the UHC. Every year there are
remarkable developments in cancer care and treatment, but not
everyone can benefit from these advances in medical science.
The challenges being faced by developed and developing
countries are also starting to converge. Around the world, and
particularly in Asia, there are concerns that economic growth
is slowing. Under this severe situation we need a great degree
of intelligence to judge the health economy. It is to be hoped
that this session will represent a small step in gathering such
intelligence.
Tomoyuki Kitagawa (Japan National Committee for UICC)
mentioned a small but important concern in Japan with regard
to UHC. He noted that, while he understood the concept of
UHC, there is no appropriate Japanese translation for the term
“universal health coverage” and even in Japanese language
materials it is usually used in its English form. Although the
term may be understood by health-care professionals it will be
very difficult for members of the public to understand unless
an appropriate Japanese translation can be devised, that would
also be media-friendly. It is important to make the concept of
UHC more understandable in all countries in Asia as part of
efforts toward Asianization.
Tetsuo Noda (UICC Board Member, Cancer Institute of
Japanese Foundation for Cancer Research) noted that there are
many differences between the countries of Asia in terms of
cancer treatment and control. However, it is annual meetings,
such as this, the 74th Annual Meeting of the Japanese Cancer
Association, that provide excellent opportunities for people
from different countries and different areas of specialty to
come together. It is important for members of the cancer com-
munity in Asia to meet together regularly and share informa-
tion and to make joint efforts to highlight the issues that Asia
faces. This UICC international session has made an important
contribution in that regard.
Shigeo Horie noted that UHC is an admirable and attractive
idea, but it also presents unique challenges for health policy.
One factor for this challenge is that there is a lack of facilita-
tion and transition between various aspects of cancer control,
including prevention, treatment, and palliative care. The
involvement of the general public is also important, particu-
larly in preventive education.
It was also noted that the World Bank and the WHO have
jointly developed a set of indicators for assessing the progress
of UHC, and these could be utilized in the future. In addition,
it was suggested that economic uncertainty could possibly pro-
vide impetus towards UHC as it was in the 1997–1998 finan-
cial crisis that concern about health-care coverage peaked in
Korea, following which UHC for cancer care was
implemented.
Shinjiro Nozaki noted that the WHO Kobe Centre will be
working to translate WHO documents into Japanese and seeks
to advance collaboration with the Japanese government and
academic institutions.
Jae Kyung Roh thanked all presenters and attendees and
closed the session.
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